Adalimumab, Infliximab and Etanercept Biosimilars Market Report 2026

Adalimumab, Infliximab and Etanercept Biosimilars Market Overview

• Adalimumab, Infliximab and Etanercept Biosimilars market size has reached to $4.96 billion in 2025 • Expected to grow to $8.05 billion in 2030 at a compound annual growth rate (CAGR) of 10.1% • Growth Driver: Impact Of Rising Autoimmune Disease Prevalence On The Adalimumab, Infliximab, And Etanercept Biosimilars Market • Market Trend: Technological Advancements in Adalimumab, Infliximab, and Etanercept Biosimilars Market to Enhance Patient Experience and Market Accessibility • North America was the largest region in 2025.

What Is Covered Under Adalimumab, Infliximab and Etanercept Biosimilars Market?

Adalimumab, infliximab, and etanercept biosimilars refer to a novel class of medications that work to inhibit the effects of the inflammatory mediator tumor necrosis factor-alpha (TNF-alpha). A chimeric monoclonal antibody against tumor necrosis factor-alpha (TNF-alpha) is known as an infliximab biosimilar. Immune system disorders are treated with it. The main types of products in adalimumab, infliximab, cipleumab, and etanercept. Adalimumab is a biological drug that works on the immune system to lessen inflammation. The different applications include Crohn’s disease, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, plaque psoriasis, and others, and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Adalimumab, Infliximab and Etanercept Biosimilars Market Growth Forecast?

The adalimumab, infliximab and etanercept biosimilars market size is expected to see rapid growth in the next few years. It will grow to $8.05 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to advancements in precision medicine, expansion of biosimilar pipelines, rising healthcare expenditure, increasing adoption of digital health solutions, growing geriatric population. Major trends in the forecast period include biosimilar adoption and market penetration, cost-effective tnf-alpha inhibitor development, regulatory approvals and policy support, expansion of hospital and retail pharmacy networks, personalized treatment protocols.

What Is The Driver Of The Adalimumab, Infliximab and Etanercept Biosimilars Market?

The rising prevalence of autoimmune diseases is expected to propel the growth of the adalimumab, infliximab, and etanercept biosimilars market going forward. Autoimmune disease refers to illnesses or disorders brought on by immune system dysfunction, in which the body's healthy cells are attacked by immune cells. Adalimumab, infliximab, and etanercept are biological drugs with tumor necrosis factor (TNF) alpha inhibitors used to treat various autoimmune diseases. For instance, in 2023, according to Johns Hopkins University, a US-based private research university, about 10 million people in the US, or 3% of the population, are affected by all autoimmune illnesses. Therefore, the rising prevalence of autoimmune diseases drives the growth of the adalimumab, infliximab, and etanercept biosimilars market.

Key Players In The Global Adalimumab, Infliximab and Etanercept Biosimilars Market

Major companies operating in the adalimumab, infliximab and etanercept biosimilars market are Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad

Global Adalimumab, Infliximab and Etanercept Biosimilars Market Trends and Insights

Major companies operating in the adalimumab, infliximab, and etanercept biosimilars market are focusing on technological advancements, such as high‑concentration, citrate‑free biosimilars, to meet the rising demand for more patient‑friendly formulations, greater affordability, and expanded market access. These high-concentration, citrate-free versions offer the same therapeutic monoclonal antibody structure as traditional biosimilars but with a more comfortable injection experience (less sting on administration), potentially improving adherence and switching rates versus conventional buffered formulations. For instance, in June 2023, Celltrion USA, a US-based biopharmaceutical company, launched Yuflyma (adalimumab-aaty), a citrate-free, high‑concentration (100 mg/mL) biosimilar of Humira (adalimumab), designed to deliver the same potency and efficacy in a more patient‑friendly format. Yuflyma provides the full therapeutic effect of adalimumab, with the added benefit of improved tolerability due to reduced injection pain, and supports broader uptake in the immunology market, particularly for chronic inflammatory diseases.

What Are Latest Mergers And Acquisitions In The Adalimumab, Infliximab and Etanercept Biosimilars Market?

In November 2024, Celltrion, a South Korea-based therapeutics company, acquired iQone Healthcare for an undisclosed amount. With this acquisition, Celltrion aims to accelerate direct commercialization of its biosimilars in the European region, enhancing market presence, expanding distribution networks, and strengthening access to innovative therapies. iQone Healthcare is a Switzerland-based pharmaceutical company that specialization in manufacturing and commercialization of biosimilars and innovative treatments for rare diseases.

What Defines the Adalimumab, Infliximab and Etanercept Biosimilars Market?

The adalimumab, infliximab, and etanercept biosimilars market consists of sales of Amgevita, Hyrimoz, and Idacio. Values in this market are ""factory gate values,"" that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Adalimumab, Infliximab and Etanercept Biosimilars Market Report 2026?

The adalimumab, infliximab and etanercept biosimilars market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the adalimumab, infliximab and etanercept biosimilars industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.